ORKA Oruka Therapeutics, Inc.

QT91

Latest market price

99.55

+4.12+4.32%

Overview Short InterestFilings

ORKAQT91Oruka Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

99.55+4.32%

News

Up 4.3% — Oruka Therapeutics to Participate in Multiple Upcoming Conferences (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RYTM-7.49%$86.44 KOD+1.29%$98.89 BLTE-0.98%$152.17 LGND+2.12%$313.52 IMVT+2.22%$29.04 IONS-1.99%$40.42 AXSM+2.65%$139.61 MIRM+1.50%$87.03

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.47	Insider Own	16.45%	Shs Outstand	66.21M	Perf Week	3.90%

Market Cap	6.32B	Forward P/E	—	EPS next Y	-2.83	Insider Trans	-36.86%	Shs Float	56.89M	Perf Month	17.98%

Enterprise Value	5.45B	PEG	—	EPS next Q	-0.60			Short Float	10.74%	Perf Quarter	2.43%

Income	-133.00M	P/S	—	EPS this Y	—			Short Ratio	6.98	Perf Half Y	44.38%

Sales	0.00	P/B	5.67	EPS next Y	—	ROA	-11.66%	Short Interest	6.11M	Perf YTD	228.44%

Book/sh	16.84	P/C	7.23	EPS next 5Y	—	ROE	-20.76%	52W High	115.52 -13.82%	Perf Year	253.39%

Cash/sh	13.20	P/FCF	—	EPS past 3/5Y	—	ROIC	-13.88%	52W Low	25.23 294.57%	Perf 3Y	343.63%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	4.66% 5.51%	Perf 5Y	208.40%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	4.82	Perf 10Y	-81.56%

Dividend Ex-Date	Aug 29, 2024	Quick Ratio	38.51	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	68.52	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	38.51	EPS Q/Q	-19.57%	SMA20	18.14%	Beta	-0.42	Target Price	137.50

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	12.91%	Rel Volume	0.92	Prev Close	95.43

Employees	68	LT Debt/Eq	0.00	Earnings	Nov 11	SMA200	42.46%	Avg Volume	897.40K	Price	99.55

IPO Date	Aug 08, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.32% —	Net Debt/EBITDA	—	Volume	822,160	Change	4.32%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-24-26	Reiterated	Wedbush	Outperform	$165 → $120
Sep-03-26	Reiterated	Mizuho Securities		$120
Jul-01-26	Reiterated	UBS	Buy	$100 → $130
Jun-02-26	Reiterated	Piper Sandler		$75 → $180
Apr-30-26	Reiterated	Leerink Partners	Outperform	$109 → $120
Apr-29-26	Reiterated	HC Wainwright & Co.	Buy	$40 → $120
Apr-28-26	Reiterated	UBS	Buy	$50 → $100
Apr-27-26	Reiterated	Wedbush	Outperform	$85 → $165
Apr-27-26	Reiterated	Guggenheim	Buy	$125 → $200
Apr-27-26	Reiterated	BTIG	Buy	$73 → $151

Latest News· Times ET

Today

Today07:00AM

Oruka Therapeutics to Participate in Multiple Upcoming Conferencesglobenewswire.com

Oct-27-26

Oct-27-2605:37AM

Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price TargetBenzinga

Oct-26-26

Oct-26-2611:02PM

Oruka's ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Studymarketbeat.com

12:49PM

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcriptseekingalpha.com

12:45PM

Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trialbenzinga.com

07:00AM

Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasisglobenewswire.com

Oct-25-26

Oct-25-2612:00PM

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026globenewswire.com

Oct-20-26

Oct-20-2602:10AM

Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book ValueYahoo

Oct-19-26

Oct-19-2608:07AM

Oruka Therapeutics (NASDAQ:ORKA) Stock Keeps “Buy” Rating at BTIG Researchdefenseworld.net

Oct-18-26

Oct-18-2606:34AM

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far Endseekingalpha.com

Sep-24-26

Sep-24-2601:02PM

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS SaysYahoo

11:35AM

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Datazacks.com

Sep-23-26

Sep-23-2609:49AM

Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacybenzinga.com

08:52AM

Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial DataYahoo

07:00AM

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosingglobenewswire.com

Company

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	26	21	13	6	—	—	—	—	—
Research and Development	129	101	75	1	—	—	—	—	—
Other Operating Expense	-1	0	0	0	—	—	—	—	—
Operating Income	-154	-122	-88	-7	—	—	—	—	—
Interest Expense	0	0	1	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	23	17	6	2	—	—	—	—	—
Net Income Before Taxes	-133	-105	-84	-5	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-133	-105	-84	-5	—	—	—	—	—
Net Income From Continuing Operations	-133	-105	-84	-5	—	—	—	—	—
Net Income	-133	-105	-84	-5	—	—	—	—	—
EPS (Recurring)	-2.47	-2.31	-4.99	-4.44	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.47	-2.31	-4.99	-4.44	—	—	—	—	—
EPS (Diluted)	-2.47	-2.31	-4.99	-4.44	—	—	—	—	—
EBITDA	-142	-105	-82	-5	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	63	46	17	14	—	—	—	—	—
Market Capitalization	6,272	1,394	330	286	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Klein Lawrence Otto	Chief Executive Officer	Nov 02 '26	Option Exercise	7.80	25,000	195,000	948,128	Nov 02
Klein Lawrence Otto	Chief Executive Officer	Nov 02 '26	Sale	95.61	25,000	2,390,125	923,128	Nov 02
Quinlan Paul T	General Counsel	Oct 20 '26	Option Exercise	7.80	9,000	70,200	38,995	Oct 20
Quinlan Paul T	General Counsel	Oct 20 '26	Sale	78.53	9,000	706,735	29,995	Oct 20
Goncalves Joana	Chief Medical Officer	Oct 15 '26	Option Exercise	7.32	7,000	51,240	38,771	Oct 15
Goncalves Joana	Chief Medical Officer	Oct 15 '26	Sale	74.81	7,000	523,648	31,771	Oct 15
Agarwal Arjun	Senior Vice President, Finance	Oct 12 '26	Option Exercise	15.69	9,999	156,904	24,218	Oct 13
Agarwal Arjun	Senior Vice President, Finance	Oct 12 '26	Sale	80.60	9,999	805,888	14,219	Oct 13
Klein Lawrence Otto	Chief Executive Officer	Oct 01 '26	Sale	83.62	25,000	2,090,593	923,128	Oct 02
Klein Lawrence Otto	Chief Executive Officer	Oct 01 '26	Option Exercise	7.80	25,000	195,000	948,128	Oct 02
Quinlan Paul T	General Counsel	Sep 21 '26	Sale	93.64	10,000	936,418	29,995	Sep 21
Quinlan Paul T	General Counsel	Sep 21 '26	Option Exercise	7.80	10,000	78,000	39,995	Sep 21
Agarwal Arjun	Senior Vice President, Finance	Sep 21 '26	Sale	95.75	533	51,035	14,219	Sep 21
Goncalves Joana	Chief Medical Officer	Sep 15 '26	Sale	92.38	7,947	734,145	31,771	Sep 15
Sandler Laura Lee	Chief Operating Officer	Sep 15 '26	Sale	95.71	906	86,713	235,478	Sep 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.